Kura Oncology (Nasdaq: KURA) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4) to five new employees. On July 1, 2026, the compensation committee granted nonstatutory stock options for 68,750 shares at a per-share exercise price of $10.78, vesting over four years.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The announcement centers on 68,750 inducement stock options at a $10.78 exercise price for five new ...
Analysis
The announcement centers on 68,750 inducement stock options at a $10.78 exercise price for five new hires, a standard Nasdaq Rule 5635(c)(4) grant, against a backdrop of elevated short positioning and earlier shareholder approval of expanded equity plans.
Key Figures
Inducement option shares:68,750 sharesNew employees:5 employeesExercise price:$10.78 per share+3 more
6 metrics
Inducement option shares68,750 sharesNonstatutory stock options granted to new employees
New employees5 employeesRecipients of inducement stock option awards
Exercise price$10.78 per shareClosing price on July 1, 2026 for option grant
Vesting period4 yearsTotal vesting duration for inducement options
Initial vesting25% after 1 yearPortion of shares vesting on first anniversary
Subsequent vesting36 monthsRemaining shares vest monthly over 36 months
FIT‑001 Phase 1a results for darlifarnib plus adagrasib in KRAS G12C tumors.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows multiple positive clinical updates followed by negative next‑day moves, indicating a tendency for the stock to sell off on good news.
"granted inducement awards consisting of nonstatutory stock options to purchase"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"Each stock option has an exercise price equal to $10.78 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement datefinancial
"on the one-year anniversary of the applicable vesting commencement date and"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five (5) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $10.78 per share, the closing price of the Company’s common stock on July 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
What inducement grants did Kura Oncology (KURA) announce on July 3, 2026?
Kura Oncology announced nonstatutory stock options to purchase 68,750 shares for five new employees. According to Kura Oncology, these options were granted under the 2023 Inducement Option Plan as material inducements to employment in line with Nasdaq Listing Rule 5635(c)(4).
What is the exercise price of the new Kura Oncology (KURA) inducement stock options?
The new Kura Oncology inducement stock options have an exercise price of $10.78 per share. According to Kura Oncology, this equals the closing price of its common stock on July 1, 2026, the date the options were granted to new employees.
How do the Kura Oncology (KURA) inducement stock options vest for new employees?
The Kura Oncology inducement stock options vest over four years. According to Kura Oncology, 25% of the shares vest on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, subject to continued service.
How many shares are covered by Kura Oncology (KURA) July 2026 inducement option grants?
The July 2026 inducement grants cover options to purchase 68,750 Kura Oncology common shares. According to Kura Oncology, these options were awarded to five new employees under the 2023 Inducement Option Plan, as amended, with standard plan and agreement terms applying.
Under which plan were the July 2026 Kura Oncology (KURA) inducement options granted?
The July 2026 inducement options were granted under Kura Oncology’s 2023 Inducement Option Plan, as amended. According to Kura Oncology, the grants are also governed by individual stock option agreements outlining applicable terms and conditions for each new employee recipient.
